Key result
Transcatheter aortic valve implantation showed comparable 30-day mortality and morbidity to surgical aortic valve replacement, with shorter ICU stays but higher long-term all-cause mortality.
Why the study?
Does TAVI improve clinical effectiveness and safety compared to S-AVR in patients with severe aortic stenosis?
Population
187 consecutive patients with severe aortic stenosis
Comparison
Transcatheter aortic valve implantation vs Surgical aortic valve replacement (S-AVR) (n=81)
Design
Cohort
Follow-up
1 year and later follow-up
Authors
Loading...
TAVI may offer short-term ICU advantages in severe AS; leaves open long-term mortality questions in non-randomized data.
Cohort (n=187)
Does TAVI improve clinical effectiveness and safety compared to S-AVR in patients with severe aortic stenosis?
TAVI demonstrates comparable short-term mortality and morbidity to S-AVR, with potentially lower long-term cardiac mortality in matched patients, supporting its use as an effective alternative for severe aortic stenosis.
Fusari et al. (2012) conducted a cohort in severe aortic stenosis (n=187). Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (S-AVR) was evaluated on Thirty-day mortality and morbidity. Transcatheter aortic valve implantation showed comparable 30-day mortality and morbidity to surgical aortic valve replacement, with shorter ICU stays but higher long-term all-cause mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: